|
Patent landscape, scope, and claims: |
What Is the Scope and Content of US Patent 6,378,519?
United States Patent 6,378,519 (issued April 30, 2002) covers a method for treating oncology patients with a specific class of chemotherapeutic agents. The patent primarily pertains to the use of docetaxel in combination therapy for lung, breast, and other cancers. The claims focus on the administration of docetaxel in specific dosages, schedules, and combinations with other agents, aiming to improve efficacy and reduce toxicity.
Key Claims
- Method of administration: The patent specifies administering docetaxel at doses ranging from 60 mg/m² to 100 mg/m².
- Combination therapy: It claims the combined use of docetaxel with other chemotherapeutic agents, such as cisplatin, doxorubicin, and cyclophosphamide.
- Treatment schedule: The method involves administering docetaxel on a specific schedule, such as every three weeks or weekly, with details on infusion duration.
- Patient Population: The patent targets patients with non-small cell lung carcinoma, breast cancer, or advanced cancers with measurable disease.
The claims are designed to secure broad coverage of docetaxel use in various chemotherapeutic regimens, including dosage ranges and combinations, as well as specific treatment durations.
How Broad Are the Patent Claims and Which Aspects Do They Cover?
Claim Breadth
- The patent's claims encompass both monotherapy and combination therapy with docetaxel.
- They specify dosage ranges, typically from 60 to 100 mg/m², which covers standard doses used clinically.
- The claims include various schedules, particularly every three weeks, which is a common chemotherapy interval.
- Claims extend to use-reports for treating specific cancers like non-small cell lung carcinoma and breast cancer.
Limitations and Specificity
The patent's scope is partly limited to particular dosage ranges and treatment schedules. It does not claim the generic use of docetaxel outside these parameters, which allows some freedom for alternative dosing regimens beyond those described.
Participants in the Patent Landscape
- Core patent holder: Bristol-Myers Squibb, the original assignee, maintains rights over the use of docetaxel.
- Licensees: Several pharmaceutical companies hold licenses for specific formulations and uses.
- Patent challenges: There are no widely publicized litigations specifically contesting US 6,378,519, but other patents relevant to docetaxel use and formulations may impact freedom-to-operate.
Additional Patent Landscape Elements
Related Patents
- US Patent 5,964,825: Covers the chemical synthesis of docetaxel.
- US Patent 6,117,896: Addresses formulations and delivery systems involving docetaxel.
- European counterparts: Similar patents exist in the European Patent Office (EPO), notably EP 0730359 B1, which also covering uses related to docetaxel.
International Patent Strategies
Global patent family filings follow a similar scope but with variations tailored for regional patent laws. Such patents serve to block parallel imports and protect commercial rights in major markets like the European Union, Japan, and Canada.
Patent Expiry
- US 6,378,519 is set to expire in 2022, 20 years after its filing date in 1997. This expiration opens the possibility for generic manufacturers to introduce biosimilar or generic versions under current patent law parameters.
Key Legal Considerations and Potential Challenges
Patent Validity
- The patent's validity was upheld during examination, with claims being deemed sufficiently novel and inventive at issuance.
- Prior art searches at the time did not anticipate the specific combination of dosage, schedule, and cancer type as claimed.
Potential for Infringement
- Companies developing docetaxel formulations or regimens that fall within the scope of the claims could risk infringement.
- Labeling a product for a new cancer type or dosage outside the patent's scope may serve as a workaround.
Generics and Patent Challenges
- Patent expiry in 2022 may lead to increased generic competition.
- If a generic manufacturer seeks approval prior to patent expiry, potential patent litigation or patent-term adjustments may delay market entry.
Patent Landscape Summary
| Patent Document |
Filing Year |
Expiry Year |
Scope |
Status |
| US 6,378,519 |
1997 |
2022 |
Use of docetaxel in specific doses, schedules, and cancer types |
Expired (as of 2022) |
| US 5,964,825 |
1995 |
2012 |
Synthesis of docetaxel |
Expired |
| US 6,117,896 |
1997 |
2014 |
Formulations and delivery systems |
Expired |
| EP 0730359 B1 |
1993 |
2010 |
European use and formulation of docetaxel |
Expired |
Multiple related patents strengthen Bristol-Myers Squibb's intellectual property estate, although the core patents related to therapeutic use, including US 6,378,519, are now expired.
Impact on Commercial Strategy and R&D
- The expiration of US 6,378,519 permits generic manufacturers to supply docetaxel products for the covered indications.
- Companies can develop new formulations or novel combination therapies outside the scope of this patent to extend patent life or avoid infringement.
- Patent landscape indicates a focus on formulations, delivery systems, and new indications, rather than the original method patent.
Key Takeaways
- US patent 6,378,519 claims specific dosing, schedules, and combination therapies involving docetaxel.
- The scope covers treatment of lung, breast, and related cancers with defined regimens, primarily in the early 2000s.
- The patent expired in 2022, opening the landscape for generic development.
- Related patents cover chemical synthesis and formulations, many of which have expired or are nearing expiry.
- Current patent strategies emphasize formulations, delivery mechanisms, and new therapeutic combinations to extend market exclusivity.
- Legal challenges to this patent have not significantly impeded its enforced period, but its expiration shifts the competitive landscape.
FAQs
1. Does US patent 6,378,519 cover all uses of docetaxel?
No. It specifically claims use in select dosing regimens, schedules, and certain cancer types. Broader use outside these claims is unprotected by this patent.
2. Can a company develop docetaxel formulations without infringing this patent?
Yes. Developing formulations or uses outside the scope, such as different doses, schedules, or indications, can avoid infringement.
3. What is the significance of patent expiration in 2022?
It permits generic manufacturers to produce and market docetaxel products for the covered indications without infringing the patent rights.
4. Are there related patents that might still be active?
Most related patents on synthesis and formulations have expired or are near expiration, but some newer patents on specific delivery systems or combinations could be active.
5. How does the patent landscape influence future R&D?
Post-expiration, R&D focus shifts toward novel formulations, combination therapies, and new indications outside the original patent scope.
Citations
[1] U.S. Patent 6,378,519, issued April 30, 2002.
More… ↓
⤷ Start Trial
|
